Less than a month after Kadmon Pharma launched its first product – Rezurock for a complication of organ transplants – the New York company has agreed to be bought by Sanofi in a $1.9 billio
New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit the mark in a pivotal trial.
Chemists at ETH Zurich have developed a new computer process that enables the generation of active pharmaceutical ingredients at speed, based on a protein’s three-dimensio
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.